Merck inks $200 million deal for Hengrui's midstage heart disease drug
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
First-of-its-kind active cosmetic ingredient directly activates the oxytocin receptor, mimicking the dermatological effects of being in love
The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru
Subscribe To Our Newsletter & Stay Updated